Traumatic brain injury opens blood-brain barrier to stealth liposomes via an enhanced permeability and retention (EPR)-like effect

Journal of Drug Targeting

Volumn 23, Issue 9, 2015, Pages 847-853

  Boyd, Ben J ^a   Galle, Adam ^a   Daglas, Maria ^a   Rosenfeld, Jeffrey V ^a,b   Medcalf, Robert ^a  

^a MONASH UNIVERSITY   (Australia)

^b Uniformed Services University of the Health Sciences   (United States)

Author keywords

Albumin; blood brain barrier; extravasation; stealth liposomes; traumatic brain injury

Indexed keywords

ALBUMIN; CHOLESTEROL; DRUG CARRIER; LIPOSOME; PHOSPHOLIPID; CARBON; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CONTROLLED STUDY; DRUG CLEARANCE RATIO; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RETENTION; LIGHT SCATTERING; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RADIOACTIVITY; TISSUE DISTRIBUTION; TRAUMATIC BRAIN INJURY; ANIMAL; BRAIN; BRAIN INJURY; CHEMISTRY; MALE; METABOLISM; PATHOLOGY; PERMEABILITY; SCINTISCANNING; TIGHT JUNCTION;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN INJURIES; CARBON RADIOISOTOPES; LIPOSOMES; MALE; MICE; PARTICLE SIZE; PERMEABILITY; TIGHT JUNCTIONS; TRITIUM;

EID: 84944685606     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2015.1034280     Document Type: Article

References (26)

1. Rosenfeld JV, Maas AI, Bragge P, et al. Early management of severe traumatic brain injury. Lancet 2012; 380: 1088-98
2. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57: 173-85
3. Werner C, Engelhard K. Pathophysiology of traumatic brain injury. Br J Anaesth 2007; 99: 4-9
4. Kitagawa K, Matsumoto M, Tagaya M, et al. Temporal profile of serum albumin extravasation following cerebral ischemia in a newly established reproducible gerbil model for vasogenic brain edema: a combined immunohistochemical and dye tracer analysis. Acta Neuropathol 1991; 82: 164-71
5. Sashindranath M, Sales E, Daglas M, et al. The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans. Brain 2012; 135: 3251-64
6. Unterberg AW, Stover J, Kress B, Kiening KL. Edema and brain trauma. Neuroscience 2004; 129: 1019-27
7. Shlosberg D, Benifla M, Kaufer D, Friedman A. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol 2010; 6: 393-403
8. Mori T, Wang XY, Kline AE, et al. Reduced cortical injury and edema in tissue plasminogen activator knockout mice after brain trauma. Neuroreport 2001; 12: 4117-20
9. Sashindranath M, Samson AL, Downes CE, et al. Compartment-and context-specific changes in tissue-type plasminogen activator (tPA) activity following brain injury and pharmacological stimulation. Lab Investig 2011; 91: 1079-91
10. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer-chemotherapy-mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-92
11. Caraglia M, Marra M, Misso G, et al. Tumour-specific uptake of anti-cancer drugs: the future is here. Curr Drug Metab 2012; 13: 4-21
12. Kaminskas LM, McLeod VM, Porter CJH, Boyd BJ. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance. J Pharm Sci 2011; 100: 5069-77
13. Boyd BJ, Kaminskas LM, Karellas P, et al. Cationic poly-l-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats. Mol Pharm 2006; 3: 614-27
14. Kaminskas LM, McLeod VM, Kelly BD, et al. A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. Nanomed Nanotechnol Biol Med 2012; 8: 103-11
15. Kiselev MA, Gryzunov Iu A, Dobretsov GE, Komarova MN. Size of a human serum albumin molecule in solution. Biofizika 2001; 46: 423-7
16. Rashid H, Muzammil S, Tayyab S. Comparison of bilirubin binding and other molecular properties of tile serum albumin of several mammalian species. IUBMB Life 1998; 44: 165-73
17. Kaminskas LM, Boyd BJ, Karellas P, et al. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers. Mol Pharm 2008; 5: 449-63
18. Takanashi Y, Ishida T, Kirchmeier MJ, et al. Neuroprotection by intrathecal application of liposome-entrapped fasudil in a rat model of ischemia. Neurol Med-Chir 2001; 41: 107-13
19. Allen TM, Hansen CB, Guo LS. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim Biophys Acta 1993; 1150: 9-16
20. Gillies ER, Dy E, Frechet JM, Szoka FC. Biological evaluation of polyester dendrimer: poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture. Mol Pharm 2005; 2: 129-38
21. Kaminskas LM, Kelly BD, McLeod VM, et al. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers. Mol Pharm 2009; 6: 1190-204
22. Lee CC, Gillies ER, Fox ME, et al. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc Natl Acad Sci USA 2006; 103: 16649-54
23. Ishida T, Takanashi Y, Doi H, et al. Encapsulation of an antivasospastic drug, fasudil, into liposomes, and in vitro stability of the fasudil-loaded liposomes. Int J Pharm 2002; 232: 59-67
24. Xiao G, Gan L-S. Receptor-mediated endocytosis and brain delivery of therapeutic biologics. Int J Cell Biol 2013; 2013: 1-14
25. Liddelow SA, Dziegielewska KM, Mollgard K, et al. Cellular specificity of the blood-CSF barrier for albumin transfer across the choroid plexus epithelium. PLoS One 2014; 9
26. Thorne RG, Nicholson C. In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space. Proc Natl Acad Sci USA 2006; 103: 5567-72